Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration

Kodiak Sciences (KOD) will report topline results from its DAYBREAK Phase 3 study on September 28, 2026.

Rhea-AI Summary

Kodiak Sciences (KOD) will report topline results from its DAYBREAK Phase 3 study on September 28, 2026.

The study evaluates Zenkuda (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) in patients with wet age-related macular degeneration. Kodiak will host a webcast at 8:30 a.m. Eastern Time that day. It will be accessible through the Events and Presentations page on Kodiak’s website, with an archived replay available for a limited time.

Argus Sep 28 session 247 alerts

+177.96% close to close 44.9x rel. volume Open Argus

Details

Market move: KOD +177.96% in the Sep 28 session. DAYBREAK Phase 3 clinical data

+170.2% Peak in 11 hr 43 min

$6.02B Mkt Cap at Peak Alert

On Sep 28, the first trading day after this news, KOD closed 177.96% above the previous close. Argus tracked a peak move of +170.2% during that session. Our momentum scanner recorded 247 alerts for this stock that day. That session’s volume was 44.9x the stock’s average daily volume.

Data tracked by StockTitan Argus for the Sep 28 session.

Key Figures

Topline results date: September 28, 2026

Topline results date

September 28, 2026

DAYBREAK Phase 3 study

Key Terms

phase 3 study, wet age-related macular degeneration

2 terms

phase 3 study technical

"Phase 3 study evaluating both Zenkuda TM and KSI-501"

A phase 3 study is the large-scale clinical trial that tests whether a new drug or medical treatment actually works and is safe in a broad group of patients, typically after earlier smaller tests. Investors watch these studies like a final dress rehearsal because their successful completion is often required for regulatory approval and market access; positive or negative results can sharply change a company’s future sales prospects and stock value.

wet age-related macular degeneration medical

"for the treatment of patients with wet age-related macular degeneration"

A severe eye condition in which abnormal, fragile blood vessels grow beneath the macula — the small central part of the retina responsible for sharp, detailed vision — and leak fluid or blood, causing rapid loss of central sight. Investors care because the condition drives demand for high-cost therapies, medical devices and ongoing care; successful treatments can create sizable markets, affect healthcare spending and influence regulatory and reimbursement decisions, much like fixing a leaking camera lens restores image quality and value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Kodiak Sciences to Host Webcast on Monday, September 28 at 8:30 AM Eastern Time

PALO ALTO, Calif., Sept. 25, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that the company will report topline results from DAYBREAK, a Phase 3 study evaluating both Zenkuda ^TM (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) for the treatment of patients with wet age-related macular degeneration, on Monday, September 28, 2026.

The webcast can be accessed at the following link DAYBREAK Topline Results Webcast or from the Events and Presentations page on Kodiak's website at https://ir.kodiak.com/events-and-presentations/events.

An archived replay of the webcast will be available for a limited time.

About Kodiak Sciences Inc.

Kodiak Sciences (Nasdaq: KOD) is a pre-commercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics. We are focused on bringing new science to the design and manufacture of next-generation retinal medicines to prevent and treat the leading causes of blindness globally. We are developing a portfolio of three late-stage clinical programs. Zenkuda™ (tarcocimab tedromer) has a BLA-ready profile in diabetic retinopathy, retinal vein occlusion and wet AMD, and KSI-501 is being evaluated in wet AMD and diabetic macular edema. Zenkuda and KSI-501 target the $15 billion anti-VEGF market across retinal vascular diseases. KSI-101 is a bispecific protein being explored in two BLA-facing Phase 3 studies in Macular Edema Secondary to Inflammation (MESI). Topline data for Pivotal Analysis 1 (PEAK) are expected in December 2026 and Pivotal Analysis 2 (PEAK+PINNACLE) in 2Q 2027.

Kodiak^®, Kodiak Sciences^®, ABC^®, ABC Platform™, Zenkuda™, VETi™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.

 

View original content:https://www.prnewswire.com/news-releases/kodiak-sciences-to-present-topline-results-on-september-28-2026-from-daybreak-pivotal-phase-3-study-of-zenkuda-and-ksi-501-in-patients-with-wet-age-related-macular-degeneration-302890661.html

SOURCE Kodiak Sciences Inc.